Cross-sex hormone treatment in male-to-female transsexual persons reduces serum brain-derived neurotrophic factor (BDNF)

Eur Neuropsychopharmacol. 2015 Jan;25(1):95-9. doi: 10.1016/j.euroneuro.2014.11.019. Epub 2014 Dec 4.

Abstract

Serum levels of brain-derived neurotrophic factor (BDNF) are reduced in male-to-female transsexual persons (MtF) compared to male controls. It was hypothesized before that this might reflect either an involvement of BDNF in a biomechanism of transsexualism or to be the result of persistent social stress due to the condition. Here, we demonstrate that 12 month of cross-sex hormone treatment reduces serum BDNF levels in male-to-female transsexual persons independent of anthropometric measures. Participants were acquired through the European Network for the Investigation of Gender Incongruence (ENIGI). Reduced serum BDNF in MtF thus seems to be a result of hormonal treatment rather than a consequence or risk factor of transsexualism.

Keywords: Estradiol; Gender dysphoria; Gender identity disorder; Neurotrophin; Testosterone; Transgender.

MeSH terms

  • Adolescent
  • Adult
  • Anthropometry / methods
  • Brain-Derived Neurotrophic Factor / blood*
  • Contraceptive Agents / therapeutic use*
  • Cyproterone Acetate / therapeutic use
  • Estradiol / analogs & derivatives
  • Estrogens
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Psychiatric Status Rating Scales
  • Retrospective Studies
  • Transgender Persons*
  • Transsexualism / blood*
  • Transsexualism / drug therapy*
  • Young Adult

Substances

  • Brain-Derived Neurotrophic Factor
  • Contraceptive Agents
  • Estrogens
  • Cyproterone Acetate
  • Estradiol